Patent intelligence · US
US 9937192
Combination therapy to treat mycobacterium diseases
Combination therapy to treat mycobacterium diseases
Patent details — US 9937192
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 10, 2018
- Expiration
- Apr 5, 2038
- Applicant
- SPERO TRINEM, INC.
- Claims
- 16
- CPC classes
- A61K, A61K31/132, A61K31/34, A61K31/4164
Quick answer
US 9937192 (Combination therapy to treat mycobacterium diseases) is held by SPERO TRINEM, INC.. Status: granted. Granted Apr 10, 2018. Expires Apr 5, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SPERO TRINEM, INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/132, A61K31/34, A61K31/4164, A61K31/4168, A61K31/421
More from SPERO TRINEM, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428395
Heterocyclic compounds as kinase inhibitor and uses thereof
granted -
US 12291548
Compounds, compositions, and methods for the treatment of disease
granted -
US 12226403
Tebipenem pivoxil immediate and modified release oral dosage forms
granted -
US 12146004
Polymyxin compounds and uses thereof
granted -
US 12098155
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
granted -
US 12048691
High dosage tebipenem pivoxil tablet formulation
granted -
US 11718621
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
granted -
US 11459357
Polymyxin compounds
granted
Frequently asked questions
What is US patent 9937192?
US 9937192 (Combination therapy to treat mycobacterium diseases) is held by SPERO TRINEM, INC.. Status: granted. Granted Apr 10, 2018. Expires Apr 5, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9937192?
SPERO TRINEM, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.
When does US 9937192 expire?
Our index shows an expiration date of Apr 5, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.